AVIR
Atea·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 0
MACD Golden Cross
Ample Liquidity
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AVIR
Atea Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company developing antiviral therapies for severe respiratory diseases, including COVID-19
225 Franklin Street, Suite 2100, Boston, MA 02110
--
Atea Pharmaceuticals, Inc., was incorporated in July 2012 and commenced primary operations in March 2014. The company is a clinical-stage biopharmaceutical company that discovers and develops novel oral product candidates for the treatment of serious viral diseases using a deep understanding of antiviral drug development, medicinal chemistry, biology, biochemistry and virology.
Company Financials
EPS
AVIR has released its 2025 Q3 earnings. EPS was reported at -0.53, versus the expected -0.41, missing expectations. The chart below visualizes how AVIR has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
